Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRVO

CervoMed Inc

Jul 26 • 04:00PM ET

14.03

Dollar change -0.34
Percentage change -2.37	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC VTWG GSSC RSSL VTHR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.08	Insider Own	35.19%	Shs Outstand	5.67M	Perf Week	-13.66%
Market Cap	115.75M	Forward P/E	-	EPS next Y	-2.82	Insider Trans	0.00%	Shs Float	5.35M	Perf Month	-23.83%
Income	-4.84M	PEG	-	EPS next Q	-0.31	Inst Own	35.10%	Short Float	11.25%	Perf Quarter	-43.86%
Sales	6.36M	P/S	18.20	EPS this Y	-97.56%	Inst Trans	-2.34%	Short Ratio	10.38	Perf Half Y	52.83%
Book/sh	0.86	P/B	16.22	EPS next Y	-74.32%	ROA	-36.66%	Short Interest	0.60M	Perf Year	196.93%
Cash/sh	0.77	P/C	18.17	EPS next 5Y	-	ROE	-44.78%	52W Range	4.28 - 26.38	Perf YTD	83.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	73.43%	ROI	-90.69%	52W High	-46.81%	Beta	1.60
Dividend TTM	-	Quick Ratio	2.90	Sales past 5Y	0.00%	Gross Margin	-	52W Low	227.80%	ATR (14)	1.76
Dividend Ex-Date	-	Current Ratio	2.90	EPS Y/Y TTM	84.51%	Oper. Margin	-157.80%	RSI (14)	35.62	Volatility	10.91% 10.99%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-76.04%	Recom	1.00	Target Price	52.60
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	86.46%	Payout	-	Rel Volume	0.72	Prev Close	14.37
Sales Surprise	-0.11%	EPS Surprise	-5.13%	Sales Q/Q	-	Earnings	May 15 BMO	Avg Volume	57.94K	Price	14.03
SMA20	-13.61%	SMA50	-24.33%	SMA200	-6.46%	Trades		Volume	41,494	Change	-2.37%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Morgan Stanley	Overweight	$35
Feb-15-24	Initiated	Canaccord Genuity	Buy	$50
Nov-17-20	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-21-18	Initiated	H.C. Wainwright	Buy	$1.25

Jul-17-24 08:00AM	CervoMed to Participate in the Emerging Growth Conference (GlobeNewswire) -6.73%
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire) +9.77%
Jul-11-24 08:51AM	CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024 (GlobeNewswire) +5.64%
Jul-10-24 10:52AM	CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:50AM	Loading…
Jun-28-24 06:50AM	Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 (InvestorPlace)
Jun-24-24 08:00AM	CervoMed Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-11-24 08:00AM	CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies (GlobeNewswire)
May-20-24 10:09AM	CervoMed Names William Elder CFO (MT Newswires) -18.06%
08:00AM	CervoMed to Appoint William Elder as Chief Financial Officer (GlobeNewswire)
May-15-24 09:54AM	CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-03-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire) -5.10%
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Apr-01-24 08:00AM	CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
04:05PM	Loading…
Mar-28-24 04:05PM	CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire) +18.76%
08:30AM	CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors (GlobeNewswire)
Mar-05-24 08:00AM	CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD 2024 (GlobeNewswire)
Feb-21-24 08:00AM	CervoMed to Participate in the BIO CEO and Investor Conference (GlobeNewswire) -7.35%
Feb-20-24 10:22AM	CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board (News Direct) -6.73%
Feb-12-24 08:00AM	CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies (GlobeNewswire) +27.12%
Feb-07-24 08:30AM	CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board (GlobeNewswire) +8.58%
07:00AM	Presenting on the Emerging Growth Conference 67 Day 2 on February 8 Register Now (GlobeNewswire)
Feb-06-24 07:00AM	Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now (GlobeNewswire)
Feb-05-24 08:00AM	CervoMed to Participate in the Emerging Growth Conference 67 (GlobeNewswire)
Jan-10-24 07:00AM	Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream (GlobeNewswire)
Jan-09-24 07:00AM	Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now (GlobeNewswire)
Jan-05-24 08:00AM	CervoMed to Participate in the Emerging Growth Conference 66 (GlobeNewswire)
Nov-13-23 07:00AM	CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights (PR Newswire)
Oct-30-23 11:21AM	CRVO: New Data from Phase 2a Trial Presented at CTAD (Zacks)
02:50PM	Loading…
Oct-25-23 02:50PM	CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies (PR Newswire) -5.44%
Oct-24-23 07:00AM	CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias (PR Newswire)
Oct-18-23 07:00AM	CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies (PR Newswire) +6.69%
Oct-05-23 07:00AM	CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference (PR Newswire)
Sep-18-23 10:40AM	CRVO: Publication in Neurology Highlights Correlation Between ptau181 Level and Response to Neflamapimod (Zacks)
Sep-05-23 07:00AM	CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire) -13.99%
Aug-21-23 08:16AM	CRVO: Initiating Coverage of CervoMed, Inc.; Phase 2b Trial in Dementia with Lewy Bodies Underway (Zacks)
Aug-15-23 04:01PM	Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma (GlobeNewswire) +7.95% +11.68%
Mar-30-23 07:00AM	EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases (GlobeNewswire) -12.78%
Dec-16-22 06:30AM	Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities (GlobeNewswire)
Dec-05-22 06:30AM	Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeScis History of Stockholder Value Destruction and Self-Dealing (GlobeNewswire) +6.89%
Dec-01-22 07:55AM	DFFN: Strategic Review Underway; Planning to Initiate Phase 2 GBM Trial in 1Q23 (Zacks Small Cap Research) -5.54%
Nov-17-22 05:20PM	LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion Pharmaceuticals (GlobeNewswire) -6.08%
Nov-14-22 04:01PM	Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.40% +14.23%
06:30AM	Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process (GlobeNewswire)
Oct-25-22 06:30AM	Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC (GlobeNewswire) +6.22%
Aug-17-22 08:52AM	DFFN: Phase 2 GBM Trial to Initiate 2H22 (Zacks Small Cap Research)
Aug-11-22 06:48PM	Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-26-22 07:30AM	Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation (GlobeNewswire) -7.31%
Jun-23-22 07:30AM	Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial (GlobeNewswire) -7.40%
May-20-22 08:10AM	DFFN: Data from Altitude Trial Expected in June 2022 (Zacks Small Cap Research)
May-18-22 07:30AM	Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer (GlobeNewswire) -6.65%
May-17-22 07:30AM	Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 04:05PM	Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.67% +12.22%
May-04-22 07:20AM	Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements (GlobeNewswire)
Apr-18-22 10:42AM	Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow (Benzinga) -34.22%
09:20AM	Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan (GlobeNewswire)
Apr-11-22 07:20AM	Diffusion Pharmaceuticals Completes Dosing in Altitude Trial (GlobeNewswire)
Apr-08-22 07:20AM	Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders (GlobeNewswire)
Apr-06-22 10:15AM	10 Biotech Penny Stocks with Growth Catalysts (Insider Monkey)
Mar-23-22 10:20AM	DFFN: Additional Tissue Oxygenation Trial Results Expected Mid-2022 (Zacks Small Cap Research) +29.98%
Mar-21-22 07:20AM	Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-09-22 04:56AM	We're Keeping An Eye On Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate (Simply Wall St.) +5.31%
Feb-24-22 07:02AM	Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts (GlobeNewswire)
Dec-20-21 07:02AM	Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during J.P. Morgan Week 2022 (GlobeNewswire)
Dec-16-21 08:59AM	Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial (GlobeNewswire)
Dec-01-21 07:02AM	Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523 (GlobeNewswire)
Nov-30-21 11:57AM	10 Biotech Penny Stocks to Buy Now (Insider Monkey) -8.16%
Nov-29-21 06:27AM	DFFN: TSC to be Developed for Treatment of Hypoxic Tumors (Zacks Small Cap Research)
Nov-22-21 07:02AM	Diffusion Pharmaceuticals Doses First Participants in Altitude Trial (GlobeNewswire) -8.51%
Nov-10-21 07:02AM	Diffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-21 07:30AM	Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference (GlobeNewswire)
Sep-10-21 07:02AM	We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate (Simply Wall St.)
Sep-09-21 07:32AM	Diffusion Pharmaceuticals Issues Letter to Shareholders (GlobeNewswire)
Sep-08-21 07:32AM	Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-30-21 07:32AM	Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDAs Pulmonology, Allergy, and Critical Care Division (GlobeNewswire) +10.20%
Aug-19-21 06:05AM	DFFN: Initial Indication for TSC to be Announced 4Q21 (Zacks Small Cap Research)
Aug-11-21 07:32AM	Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update (GlobeNewswire) -5.27%
Aug-06-21 10:20AM	10 Biotech Penny Stocks to Buy According to Reddit (Insider Monkey)
Jul-06-21 06:34AM	DFFN: TSC Causes Dose Dependent Increase in Tissue Oxygenation in TCOM Trial (Zacks Small Cap Research)
Jun-30-21 11:14AM	Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation (Benzinga)
07:35AM	Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial (GlobeNewswire)
Jun-28-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Jun-21-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021 (GlobeNewswire)
07:35AM	Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum (GlobeNewswire)
Jun-18-21 07:35AM	Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting (GlobeNewswire)
Jun-13-21 06:13PM	Diffusion Pharmaceuticals Inc. (DFFN): Hedge Funds In Wait-and-See Mode (Insider Monkey)
May-14-21 08:21AM	DFFN: Encouraging Data for TSC in COVID-19 Patients (Zacks Small Cap Research)
May-10-21 10:23AM	Diffusion Pharma's Trans Sodium Crocetinate Associated With Improved Outcomes In COVID-19 Patients (Benzinga) +12.85%
07:50AM	Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients (GlobeNewswire)
07:05AM	Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-21 11:47AM	DFFN: Three Studies to Guide Clinical Development of TSC (Zacks Small Cap Research)
09:01AM	Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study (GlobeNewswire)
Mar-18-21 07:05AM	Diffusion Pharmaceuticals Doses First Participants in TCOM Study (GlobeNewswire)
Mar-17-21 07:05AM	Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update (GlobeNewswire) +5.88%
Mar-14-21 04:47AM	We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate (Simply Wall St.)
Mar-04-21 04:05PM	Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) -12.14%
Feb-18-21 04:05PM	Diffusion Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock (GlobeNewswire) -8.33%
Feb-17-21 04:13PM	Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock (GlobeNewswire) -12.35%
07:26AM	The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal (Benzinga)

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRVO

CervoMed Inc

Upgrade your FINVIZ experience